Most assessments of value in healthcare continue to focus on the traditional clinical indicators of safety, efficacy, and cost-effectiveness. A new generation of innovative therapies (such as gene therapies, CAR-Ts, BiTEs) provide gains across a broad set of metrics, including reducing the burden of illness on patients and caregivers. These experiential humanistic, social, and economic benefits may be difficult to capture and quantify, leading to a systematic under-reporting and under-appreciation of their value.

Exploration and demonstration of evidence beyond well-established evaluation norms will be increasingly important as additional factors are considered as part of the holistic decision-making process. Evidence such as patient experience on- and off-therapy, “peace of mind” from reduced or eliminated overall disease burden, the “value of knowing” even in absence of therapy indications, and improved health equity are increasingly being incorporated into the decision-making process, but standardized assessments of these metrics have not been established.

A collaborative approach across manufacturer, payer, healthcare provider, and patient stakeholders is required to demonstrate differentiated value for new innovations and expand the context in which healthcare decision making is accomplished. Manufacturers are not always best equipped to support this differentiated evidence creation and effectively communicate that differentiation to diverse stakeholders including US payers and ex-US HTA bodies.

Our group of panelists representing Medical Affairs, HEOR, and Market Access professionals will discuss how newer, non-traditional evidence can be developed and successfully incorporated into value communication to drive appropriate therapy access and utilization. They will speak from their first-hand professional experiences about the hurdles they encountered and how they overcame those hurdles to ultimately help patients get access to much-needed treatments. In summation, they will discuss how effective cross-functional collaboration internally within life sciences companies is key to an efficient and effective value communication strategy externally.

Sponsor: Trinity Lifesciences